Dubois Steven G, London Wendy B, Zhang Yang, Matthay Katherine K, Monclair Tom, Ambros Peter F, Cohn Susan L, Pearson Andrew, Diller Lisa
Department of Pediatrics, University of California, San Francisco, California, USA.
Pediatr Blood Cancer. 2008 Nov;51(5):589-92. doi: 10.1002/pbc.21684.
Neuroblastoma is the most common extracranial pediatric solid cancer. Lung metastasis is rarely detected in children with newly diagnosed neuroblastoma. We aimed to describe the incidence, clinical characteristics, and outcome of patients with lung metastasis at initial diagnosis using a large international database.
The subset of patients from the International Neuroblastoma Risk Group database with INSS stage 4 neuroblastoma and known data regarding lung metastasis at diagnosis was selected for analysis. Clinical and biological characteristics were compared between patients with and without lung metastasis. Survival for patients with and without lung metastasis was estimated by Kaplan-Meier methods. Cox proportional hazards methods were used to determine the independent prognostic value of lung metastasis at diagnosis.
Of the 2,808 patients with INSS stage 4 neuroblastoma diagnosed between 1990 and 2002, 100 patients (3.6%) were reported to have lung metastasis at diagnosis. Lung metastasis was more common among patients with MYCN amplified tumors, adrenal primary tumors, or elevated lactate dehydrogenase (LDH) levels (P < 0.02 in each case). Five-year overall survival +/- standard error for patients with lung metastasis was 34.5% +/- 6.8% compared to 44.7% +/- 1.3% for patients without lung metastasis (P = 0.0002). However, in multivariable analysis, the presence of lung metastasis was not independently predictive of outcome.
Lung metastasis at initial diagnosis of neuroblastoma is associated with MYCN amplification and elevated LDH levels. Although lung metastasis at diagnosis was not independently predictive of outcome in this analysis, it remains a useful prognostic marker of unfavorable outcome.
神经母细胞瘤是儿童最常见的颅外实体癌。新诊断的神经母细胞瘤患儿很少检测到肺转移。我们旨在使用一个大型国际数据库描述初诊时发生肺转移患者的发病率、临床特征和预后。
从国际神经母细胞瘤风险组数据库中选取诊断为国际神经母细胞瘤分期系统(INSS)4期神经母细胞瘤且有诊断时肺转移相关数据的患者子集进行分析。比较有和无肺转移患者的临床和生物学特征。采用Kaplan-Meier方法估计有和无肺转移患者的生存率。使用Cox比例风险方法确定诊断时肺转移的独立预后价值。
在1990年至2002年诊断为INSS 4期神经母细胞瘤的2808例患者中,100例(3.6%)报告在诊断时有肺转移。肺转移在MYCN扩增肿瘤、肾上腺原发性肿瘤或乳酸脱氢酶(LDH)水平升高的患者中更常见(每种情况P<0.02)。有肺转移患者的5年总生存率±标准误为34.5%±6.8%,无肺转移患者为44.7%±1.3%(P = 0.0002)。然而,在多变量分析中,肺转移的存在并非独立预后因素。
神经母细胞瘤初诊时的肺转移与MYCN扩增和LDH水平升高相关。尽管在本分析中诊断时的肺转移并非独立预后因素,但它仍然是不良预后的一个有用的预后标志物。